Skip to main content
. 2013 Oct 25;3:3050. doi: 10.1038/srep03050

Figure 3. Validation of the PTX and NK105 distribution within the tumour tissues by MS/MS analysis.

Figure 3

(a) The structure of PTX is shown. (b) (c) The PTX-specific MS/MS fragments at m/z 224.06, 547.17, 607.19, and 832.26 are shown in (b). The fragment pattern from MS/MS analysis of the tumour tissue sample is shown in (c). (d) (e) Images obtained by optical microscopy (left) and by MS/MS analysis of PTX (m/z 607.19*) (right) in tumours treated with PTX (d) or NK105 (e) at 1 h after injection. Bar, 500 μm.